Mont-Saint-Guibert, Belgium, August 26, 2025, 08:30 am CET – regulated information / inside information – Celyad Oncology (Euronext: CYAD) (“Celyad” or the “Company”), today announced that it has decided to discontinue its research and development (R&D) activities and to implement a significant reduction in its R&D workforce due to limited cash resources.
This decision follows a comprehensive review of the Company’s operations, limited resources and results, and strategic options. Celyad will continue to focus its efforts on the management and licensing of its intellectual property portfolio.
Matt Kane, Chief Executive Officer of Celyad: “Celyad has long been at the forefront of innovation in CAR-T cell therapy. While this decision was not easy to make, we believe that focusing on our intellectual property portfolio is the most effective way to leverage our scientific achievements and proprietary technologies. We are committed to supporting our employees through this transition and to exploring possible collaborations with potential partners to unlock the potential of our IP assets.”
Management currently anticipates that existing cash resources will fund operations into mid Q4 2025. Given this limited cash runway, the Company continues to assess strategic options but expects that additional financing or further cost cutting measures will likely be required to support continuing operations, and Management will maintain a disciplined focus on streamlining operations and cost-containment. The Company additionally intends to sell its remaining assets to allow it to fully focus on optimizing the potential of its IP portfolio.
